PICI Survey

Cancer immunotherapy or checkpoint inhibitors are among the most promising new cancer therapies. By activating T-cells, they can attack cancer cells but this can also result in development of autoimmunity. PICI is studying autoimmune conditions following check-point inhibition treatment of cancer. Through partnerships with the National Cancer Care Alliance and Precision Cancer Research, PICI is collecting clinical data and blood samples from patients during their cancer treatment with immunotherapy. The RESPOND HEALTH Platform is then used to monitor autoimmune symptoms so additional samples can be taken and studied.